Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4
- PMID: 17846341
- DOI: 10.1161/CIRCULATIONAHA.107.726307
Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4
Comment on
-
Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis.Circulation. 2007 Sep 11;116(11):1258-66. doi: 10.1161/CIRCULATIONAHA.106.683227. Epub 2007 Sep 4. Circulation. 2007. PMID: 17785623
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources